Evidence map›Paper›PMID 29230227›Full record

ArticleFrontiers in immunology2017

Anti-idiotypic Antibodies against BP-IgG Prevent Type XVII Collagen Depletion.

Mayumi Kamaguchi, Hiroaki Iwata, Yuiko Mori, Ellen Toyonaga, Hideyuki Ujiie, Yoshimasa Kitagawa, Hiroshi Shimizu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Modes of Action of Intravenous Immunoglobulin in Bullous Pemphigoid.The Journal of investigative dermatology · 2018
    Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mayumi KamaguchiDepartment of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Hiroaki IwataDepartment of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Yuiko MoriDepartment of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Ellen ToyonagaDepartment of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Hideyuki UjiieDepartment of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Yoshimasa KitagawaDepartment of Oral Diagnosis and Medicine, Graduate School of Dental Medicine, Hokkaido University, Sapporo, Japan.
Hiroshi ShimizuDepartment of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Hokkaido University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bullous pemphigoid (BP) mainly targets type XVII collagen (COL17). Intravenous immunoglobulin (IVIg) is used to treat numerous autoimmune diseases, including BP. The major mechanism of action for IVIG is thought to be its immunomodulatory effect. However, little is known about the precise mechanisms of IVIg in BP. We investigate the cellular effects of IVIg, toward treatments for BP. Keratinocytes were treated with IgG from BP patients (BP-IgG) and with IVIg, and then the COL17 expression was detected by Western blotting. Cell adhesion and

Indexed as

autoantibodybullous pemphigoiddepletionidiotypic antibodyintravenous immunoglobulintype XVII collagen

Identifiers

PMID29230227
PMCPMC5712008
OpenAlexW2769722424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.